Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00199459
Other study ID # R-04-481
Secondary ID PSI 04-041
Status Completed
Phase N/A
First received September 12, 2005
Last updated September 2, 2009
Start date January 2005
Est. completion date November 2008

Study information

Verified date September 2009
Source Lawson Health Research Institute
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Observational

Clinical Trial Summary

Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies.


Description:

Urinary stone disease affects 10% of the Canadian population during their lifetime and approximately half of these patients will have another episode within ten years. Currently, patients undergo metabolic testing (serum and 24 hour urine tests) to identify modifiable risk factors; however, no modifiable risk factors are identified in many patients, yet they continue to form stones. New techniques must be developed to identify stone patients at risk for future recurrences and ultimately to develop more specific prevention strategies.

Urinary protein levels are not routinely measured in stone patients while there is strong evidence that proteins play a role in the etiology of stones. The purpose of this study is to examine the urinary and serum proteins of stone formers compared to healthy subjects utilizing the high throughput method, Surface Enhanced Laser Desorption/Ionization (SELDI). We hypothesize that there is a unique set of proteins expressed in serum and urine in stone patients that can be detected by SELDI. Once a protein is identified as a biomarker, a specific assay similar to a quick and affordable dipstick test may be developed to identify those stone patients at risk of future stones. Ultimately, this will better our understanding of stone disease and help develop new prevention strategies.

Comparisons: protein profiles (serum/urine) of stone patients both during the presence of a stone and 6 weeks after they have passed it. comparison of stone profiles of stone patients with controls (non-forming stone patients).


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date November 2008
Est. primary completion date November 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Controls:

- Ages 18 to 65 years of age

- No history of stone disease and no radiographical evidence of stone (as demonstrated by negative ultrasound)

- No family history of stones

- Healthy and no autoimmune or systemic disease that may affect renal function (see exclusion criteria)

Stone patients

- Ages 18 to 65 years of age

- Solitary stone of any size, in any location along the urinary tract (except lower renal calyceal stones and bladder stones)

- Radiology of any modality proving the existence of the stone (ultrasound, computed tomography, intravenous pyelogram, kidney-ureter-bladder x-ray)

Exclusion Criteria:

- ALL:

- Pregnant females

- Male patients treated for with benign prostate hyperplasia (BPH) (ongoing medical treatment or surgical intervention within 6 months)

- Positive urine culture

- Any cancer (excluding superficial skin, brain)

- Chronic Recurrent urinary infections (prostate, cystitis, vaginosis/vaginitis)

- Gross hematuria

- Autoimmune disease that may affect renal function (eg Systemic lupus erythematosus)

- Renal dysfunction or its common causes:

- Diabetes

- Uncontrolled hypertension (with concurrent microalbuminuria) (diastolic BP > 90 mmHg)

- glomerulonephritis

- Renal transplant

- Genetic stone disease (e.g. Cystine stones, xanthinuria)

- Medullary sponge kidney, or other renal anomalies such as horseshoe kidney

- GI disorders: Inflammatory bowel disease, short bowel

- Hypercalcemic disorders (hyperparathyroidism, sarcoidosis, Paget's disease)

- Renal tubular acidosis

- Immunodeficient patients e.g. HIV (indinavir stones)

- Unable to provide informed consent

- Anyone in the opinion of the investigator who would be inappropriate

Controls :

- In addition to criteria above.....

- persistent thiazide use

- Family history of stones (this will exclude any genetic factors since a positive family history increases the risk of urolithiasis)

Study Design

Observational Model: Case Control, Time Perspective: Prospective


Related Conditions & MeSH terms


Locations

Country Name City State
Canada St. Joseph's Health Care London London Ontario

Sponsors (3)

Lead Sponsor Collaborator
Lawson Health Research Institute The Physicians' Services Incorporated Foundation, University of Western Ontario, Canada

Country where clinical trial is conducted

Canada, 

See also
  Status Clinical Trial Phase
Recruiting NCT04924790 - The Effect of the COVID-19 on Patient Preferences and Decision Making for Obstructive Urinary Stone Interventions
Recruiting NCT05701098 - SOUND Pivotal Trial - (Sonomotion stOne comminUtion resoNance ultrasounD) N/A
Recruiting NCT05574517 - Tubeless Percutaneous Nephrolithotomy Without Reverse Insertion of a Ureteral Catheter N/A
Withdrawn NCT00388271 - Use of Alfuzosin in Stone Treatment With ESWL Phase 3
Recruiting NCT02298465 - ESWL for Distal Ureteric Stone: Supine Versus Prone N/A
Active, not recruiting NCT01973088 - Screening and Identification of Human Urate Transporter hURAT1 MicroRNA N/A
Recruiting NCT01884870 - Silent Ureteral Stone: Impact on Renal Function and Kidney Anatomy N/A
Active, not recruiting NCT00575432 - Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy
Completed NCT05027971 - Flexiva Pulse Registry
Terminated NCT00199524 - Use of a Ureteral Access Sheath During Ureteroscopy and Its Effect on Stone Free Rate Phase 4
Recruiting NCT05048706 - SP TLF Versus Ho:YAG Laser N/A
Not yet recruiting NCT04110574 - Computed Tomography Evaluation of Urinary Stones Densities Compared to in Vitro Analysis of Its Chemical Composition
Recruiting NCT02594631 - Shock Wave Lithotripsy Versus Visual Cystolitholapaxy in The Management of Patients Presenting With Calcular Acute Urinary Retention: A Randomized Controlled Trial. Phase 4
Completed NCT00857090 - Pharmacokinetic, Safety and Efficacy Study of OMS201 in Subjects Undergoing Retrograde Ureteroscopic Removal of Upper Urinary Tract Stones Phase 1/Phase 2
Completed NCT04112160 - Prospective Randomized Controlled Trial for Pain Relief After Office Ureteral Stent Removal Phase 2
Completed NCT04594161 - Effectiveness of Drainage by PCN vs. JJ in Patients With Symptoms of Obstructive Kidney Disease Caused by Urolithiasis N/A
Not yet recruiting NCT04796792 - Ultrasound to Facilitate Stone Passage N/A
Recruiting NCT05270421 - Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi Phase 3
Completed NCT02983409 - Analysis the Relationship Between the Abdomen CT and Outcomes in Acute Urinary Stone Patients N/A
Not yet recruiting NCT00397397 - Comparative Treatment Study in Patients With Lower Ureteral Stones Phase 0